OKYO Pharma (OKYO) Cash & Equivalents (2021 - 2026)

OKYO Pharma (OKYO) has reported Cash & Equivalents for 6 consecutive years, with $14.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 834.99% year-over-year to $14.6 million; the TTM figure through Mar 2026 stood at $14.6 million (up 834.99% YoY), while the FY2026 annual figure was $14.6 million, up 834.99% from the prior year.
• Cash & Equivalents advanced to $14.6 million in Q1 2026 per OKYO's latest filing, from $4.2 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $14.6 million in Q1 2026 and bottomed at $826848.0 in Q1 2024.
• Historically, Cash & Equivalents has averaged $3.8 million across 5 years, with a median of $2.2 million in 2022.
• Annual changes were most pronounced in 2024 — Cash & Equivalents sank 79.56% — and 2026, when it jumped 834.99%.
• OKYO Pharma's Cash & Equivalents stood at $2.7 million in 2022, then sank by 40.11% to $1.6 million in 2023, then tumbled by 38.97% to $987199.0 in 2024, then surged by 327.51% to $4.2 million in 2025, then soared by 245.8% to $14.6 million in 2026.
• Business Quant data shows OKYO's Cash & Equivalents at $14.6 million in Q1 2026, $4.2 million in Q3 2025, and $1.6 million in Q1 2025.